Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study

Vasopressin analogues associated with albumin improve renal function in hepatorenal syndrome (HRS). The current study was aimed at assessing the efficacy of the treatment, predictive factors of response, recurrence of HRS, and survival after therapy. Twenty‐one consecutive patients with HRS (16 with type 1 HRS, 5 with type 2 HRS) received terlipressin (0.5‐2 mg/4 hours intravenously) until complete response was achieved (serum creatinine level < 1.5 mg/dL) or for 15 days; 13 patients received intravenous albumin together with terlipressin. Twelve of the 21 patients (57%) showed complete response. Albumin administration was the only predictive factor of complete response (77% in patients receiving terlipressin and albumin vs. 25% in those receiving terlipressin alone, P = .03). Treatment with terlipressin and albumin was associated with a remarkable decrease in serum creatinine level, increase in arterial pressure, and suppression of the renin‐aldosterone system. By contrast, no significant changes in these parameters were found in patients treated with terlipressin alone. Only 1 patient showed ischemic adverse effects. Recurrence of HRS occurred in 17% of patients with complete response. The occurrence of complete response was associated with an improved survival. In conclusion, terlipressin therapy reverses HRS in a high proportion of patients. Recurrence rate after treatment withdrawal is uncommon. Albumin appears to improve markedly the beneficial effects of terlipressin.

[1]  V. Arroyo,et al.  Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. , 2002, Gastroenterology.

[2]  P. Thuluvath,et al.  Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation , 2002, Hepatology.

[3]  R. Moreau,et al.  Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. , 2002, Gastroenterology.

[4]  L. Blendis,et al.  New challenge of hepatorenal syndrome: Prevention and treatment , 2001, Hepatology.

[5]  J. Pomposelli,et al.  Live donor liver transplantation. , 2001, Journal of hepatology.

[6]  D. Pateron,et al.  Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST Study , 2000, Hepatology.

[7]  H. Schild,et al.  Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study , 2000, Gut.

[8]  R. Bataller,et al.  Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. , 2000, Journal of hepatology.

[9]  A. Gerbes,et al.  Long‐term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine , 1999, Hepatology.

[10]  P. Angeli,et al.  Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide , 1999, Hepatology.

[11]  R. Moreau,et al.  Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome , 1998, Journal of hepatology.

[12]  Rosa Gilabert,et al.  Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems , 1998, Hepatology.

[13]  W. Jiménez,et al.  Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion , 1998, Hepatology.

[14]  J. Schölmerich,et al.  Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis , 1996, Hepatology.

[15]  G. Klintmalm,et al.  Impact of pretransplant renal function on survival after liver transplantation. , 1995 .

[16]  W. Jiménez,et al.  Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. , 1993, Gastroenterology.

[17]  G. Klintmalm,et al.  Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients. , 1991, Transplantation.

[18]  Vicente Arroyo,et al.  Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis , 1988, Hepatology.

[19]  D. V. van Thiel,et al.  Effects of renal impairment on liver transplantation. , 1987, Gastroenterology.

[20]  E. Moore,et al.  Peritoneovenous shunt in the management of the hepatorenal syndrome. , 1986, Kidney international.

[21]  O. Moine,et al.  Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. , 2001, Acta gastro-enterologica Belgica.

[22]  M. Epstein.  The Kidney in liver disease , 1996 .

[23]  J. Llach,et al.  Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. , 1990, Gastroenterology.